Changeflow GovPing Pharma & Drug Safety RSV Vaccine Methods for Inactivating and Stabil...
Routine Notice Added Final

RSV Vaccine Methods for Inactivating and Stabilizing Pre-F Protein

Favicon for changeflow.com USPTO Patent Grants - Peptides (C07K)
Published
Detected
Email

Summary

USPTO granted patent US12600750B2 to Xiamen University covering methods for inactivating respiratory syncytial virus (RSV) and stabilizing pre-F protein. The patent also covers inactivated RSV virus obtained by the method, vaccines comprising the inactivated virus, and uses of the vaccine for preventing or treating RSV infection. The patent names six inventors including Zizheng Zheng, Wei Zhang, and Ningshao Xia, with 19 claims total.

What changed

USPTO granted patent US12600750B2 to Xiamen University for methods of inactivating RSV and stabilizing pre-F protein, along with the resulting inactivated virus, vaccines, and therapeutic uses. The patent claims priority to a July 2019 filing and covers 19 claims across multiple CPC classifications including C07K 14/005 and A61K 39/155.

For pharmaceutical companies and vaccine developers working on RSV immunizations, this patent may create licensing requirements or necessitate design-around strategies to avoid infringement. Researchers in the RSV vaccine space should conduct freedom-to-operate analyses before advancing programs that may fall within the scope of these claims.

What to do next

  1. Monitor for patent licensing opportunities
  2. Review freedom-to-operate implications for RSV vaccine development

Archived snapshot

Apr 14, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Methods for inactivating and storing respiratory syncytial virus

Grant US12600750B2 Kind: B2 Apr 14, 2026

Assignee

Xiamen University

Inventors

Zizheng Zheng, Wei Zhang, Lujing Zhang, Yongpeng Sun, Li Chen, Ningshao Xia

Abstract

Provided are a method for inactivating respiratory syncytial virus (RSV) and stabilizing pre-F protein in RSV and inactivated RSV virus obtained thereby. Also provided are a vaccine comprising the inactivated RSV virus and a use of the vaccine in preventing or treating RSV infection or a disease related thereto.

CPC Classifications

C07K 14/005 A61K 39/155 A61K 2039/5252 A61K 2039/575 A61K 39/12 A61P 31/14 A61P 11/00 C12N 1/04 C12N 7/00 C12N 2760/18534 C12N 2760/18561 C12N 2760/18563 C12N 2760/18571

Filing Date

2019-07-08

Application No.

17258109

Claims

19

View original document →

Named provisions

Methods for inactivating RSV Stabilizing pre-F protein Inactivated RSV virus RSV vaccine composition Use for preventing RSV infection

Get daily alerts for USPTO Patent Grants - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 14th, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US12600750B2

Who this affects

Applies to
Pharmaceutical companies Healthcare providers Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent licensing Vaccine development Biopharmaceutical research
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Public Health

Get alerts for this source

We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!